IP Library Granted Patent US 7,872,017
Granted Patent B2
US 7,872,017 · App. 11/748,527 · Granted Jan 18, 2011

Fused bicycloheterocycle substituted azabicyclic alkane derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,872,017
App. No.
11/748,527
Granted
Jan 18, 2011
Kind
B2
Abstract

The invention relates to fused bicycloheterocycle substituted azabicyclic alkane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Claims (65)

1. The compound of formula (I),

or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, wherein

n is 1, 2 or 3;

A is N or N + —O − ;

R is hydrogen, alkyl, cycloalkylalkyl and arylalkyl;

L is selected from the group consisting of O, S, and —N(R a )—;

Ar 1 is a pyridinylene group substituted with 0, 1, 2 or 3 substituents selected from the group consisting of acyl, acyloxy, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxyimino, alkoxysulfonyl, alkyl, alkylsulfonyl, alkynyl, amino, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halo, hydroxy, hydroxyalkyl, mercapto, nitro, thioalkoxy,—NR g R j , (NR g R j )alkyl, (NR g R j )alkoxy, (NR g R j )carbonyl, and (NR g R j )sulfonyl, wherein R g and R j are each independently selected from the group consisting of hydrogen and alkyl; and

Ar 2 is a bicyclic heteroaryl substituted with 0, 1, 2, or 3 substituents selected from the group consisting of alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfonyl, alkylthio, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halo, hydroxy, hydroxyalkyl, mercapto, nitro, —NR g R j , (NR g R j )alkyl, (NR g R j )alkoxy, (NR g R j )carbonyl, and (NR g R j )sulfonyl, wherein R g and R j are each independently selected from the group consisting of hydrogen and alkyl; and

R a is selected from the group consisting of hydrogen, alkyl and alkylcarbonyl.

2. The compound of claim 1 , wherein Ar 1 is selected from the group consisting of:

wherein R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of acyl, acyloxy, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxyimino, alkoxysulfonyl, alkyl, alkylsulfonyl, alkynyl, amino, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halo, hydroxy, hydroxyalkyl, mercapto, nitro, thioalkoxy, —NR g R j , (NR g R j )alkyl, (NR g R j )alkoxy, (NR g R j )carbonyl, and (NR g R j )sulfonyl;

R g and R j are each independently selected from the group consisting of hydrogen and alkyl.

3. The compound of claim 1 , wherein Ar 2 is selected from the group consisting of

wherein Z 1 , Z 2 , Z 3 and Z 4 are each independently nitrogen or are carbon, wherein the carbon atom is optionally substituted with a substituent selected from the group consisting of hydrogen, halogen, alkyl, —OR c , -alkyl-OR c , —NR d R e , and -alkyl-NR d R e ;

R b is selected from the group consisting of hydrogen, alkyl and alkylcarbonyl;

R c is alkyl;

R d and R e are each independently selected from the group consisting of hydrogen and alkyl,

R 6 and R 7 are each independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxyimino, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfonyl, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halo, hydrogen, hydroxy, hydroxyalkyl, mercapto, nitro, thioalkoxy, —NR g R j , (NR g R j )alkyl, (NR g R j )alkoxy, (NR g R j )carbonyl, and (NR g R j )sulfonyl; R g and R j are each independently selected from the group consisting of hydrogen and alkyl.

4. The compound of claim 2 , wherein

A is N; R is methyl or hydrogen; L is O; n is 2; and Ar 2 is selected from the group of consisting of:

5. The compound of claim 2 , wherein

A is N; R is methyl or hydrogen; L is O; n is 2; Ar 1 is

6. The compound of claim 2 , wherein

A is N; R is methyl or hydrogen; L is O; n is 2; Ar 1 is

7. The compound of claim 1 , selected from the group consisting of:

5-{5-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indole;

(endo)-3-(6-benzo[b]thiophen-5-yl-pyridin-3-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octane;

5-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indole;

(exo)-3-[6-(benzofuran-5-yl)-pyridin-3-yloxy]-8-methyl-8-aza-bicyclo[3.2.1]octane;

5-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indazole;

5-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-2-trifluoromethyl-1H-indole;

4-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indole;

5-{6-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-1H-indole;

(endo)-3-(5-benzo[b]thiophen-5-yl-pyridin-2-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octane;

5-{6-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-1H-indole;

[6-(1H-indol-5-yl)-pyridin-3-yl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;

[6-(benzofuran-5-yl)-pyridin-3-yl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;

[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-[6-(2-trifluoromethyl-1H-indol-5-yl)-pyridin-3-yl]-amine;

[6-(1H-indazol-5-yl)-pyridin-3-yl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;

[6-(1H-indol-4-yl)-pyridin-3-yl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;

[(endo)-8-aza-bicyclo[3.2.1]oct-3-yl]-[6-(1H-indol-5-yl)-pyridin-3-yl]-amine;

[6-(1H-indol-6-yl)-pyridin-3-yl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;

5-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-pyrrolo[2,3-b]pyridine;

5-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-1H-indole;

(endo)-N-(5-(1H-Indol-5-yl)pyridin-3-yl)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine;

(endo)-N-(5-(1H-Indol-4-yl)pyridin-3-yl)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine;

(endo)-N-(5-(1H-Indol-6-yl)pyridin-3-yl)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine;

(endo)-N-{5-[2-(trifluoromethyl)-1H-indol-5-yl]pyridin-3-yl}-8-Methyl-8-azabicyclo[3.2.1]octan-3-amine;

5-{5-[(endo)-8-Methyl-8-azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-pyrrolo[2,3-b]pyridine;

5-{5-[(endo)-8-Methyl-8-azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}indolin-2-one;

5-{5-[(endo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indole;

(1R,3r,5S,8s)-3-(6-(1H-Indol-5-yl)pyridin-3-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane 8-oxide;

(1R,3r,5S,8r)-3-(6-(1H-Indol-5-yl)pyridin-3-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane 8-oxide;

4-{5-[(endo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indole;

5-{5-[(exo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indole;

5-{5-[(endo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}indolin-2-one;

5-{5-[(endo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-pyrrolo[2,3-b]pyridine;

5-{5-[(exo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-pyrrolo[2,3-b]pyridine.

8. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically acceptable carrier.

9. A compound that is 5-{5-[(endo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indole or a salt thereof.

10. A compound that is 5-{5-[(exo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indole or a salt thereof.

11. A compound that is 5-{5-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxyl]-pyridin-2-yl}-1H-indole or a salt thereof.

12. A compound that is 5-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indole or a salt thereof.

13. A compound that is 4-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indole or a salt thereof.

14. A compound that is 5-{6-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-1H-indole or a salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030231/0808 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2007
From: JI, JIANGUO; LI, TAO; LYNCH, CHRISTOPHER L.; GOPALAKRISHNAN, MURALI
To: ABBOTT LABORATORIES
Reel/Frame 019869/0289 →